Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma

CONCLUSION: Brexu-cel has emerged as a viable treatment option in MCL. Additional studies are required to determine the optimal sequencing and place in therapy for brexu-cel in this highly heterogeneous, pathobiologically distinct, and incurable malignancy.PMID:34340597 | DOI:10.1177/10600280211026338

Source: The Annals of Pharmacotherapy - August 3, 2021 Category: Drugs & Pharmacology Authors: Mary Kate Anderson Annie Torosyan Zachery Halford Source Type: research